<!DOCTYPE html> <html><head><meta name="viewport" content="width=device-width, initial-scale=1.0"/><link href="../assets/css/extlib/bootstrap/bootstrap.css" rel="stylesheet" type="text/css" /><link href="../assets/css/style.css" rel="stylesheet" type="text/css" /><link rel="stylesheet" href="../assets/css/extlib/font-awesome/font-awesome.min.css"/><link rel="stylesheet" href="../assets/css/extlib/flaticon/flaticon.css"/><link href="../assets/css/etgcompletestyle.css" rel="stylesheet" type="text/css" /><script  src="../assets/js/extlib/jquery/jquery.min.js"></script><script  src="../assets/js/extlib/bootstrap/bootstrap.min.js"></script><script  src="../assets/js/extlib/bootstrap/bootstrapTooltip.js"></script><script src="../assets/js/extlib/bootstrap/bootstrapTransition.js"></script><script  src="../assets/js/extlib/bootstrap/offcanvas.js"></script><script src="../assets/js/lib/application.js"></script> <style> </style> </head><body class="etgtopic"  id="abg16-c130"><div class="bodyContentDiv"><span style="display:none;"><p id="MPS_d1e2"><span>Antibiotic&#x000A0;2018XXXX-XXXXXXX-X-XXXX-XXXX-X<book-name>Antibiotic</book-name></span></p></span><span id="MPS_d1e25" style="display:none;"><h1 class="main-heading" id="00001">Cellulitis and erysipelas<div class="topic-tools"><div class="container"><ul class="topic-icons showIcon"><li><a class="expertgroup" data-original-title="Expert Group" data-placement="bottom" data-target="#endorsementcontent" data-toggle="modal" data-tooltip="true" title="Expert Group"></a></li><li><a class="feedback sendFeedBack" data-contentwrapper=".mycontent" data-original-title="Feedback" id="" onclick="sendFeedbackSection('00001')" title=""></a></li><li><a class="favourite" data-original-title="Favourite topic" data-placement="bottom" data-toggle="tooltip" onclick="addFavourite('00001')" title=""></a></li></ul></div></div></h1></span><span id="MPS_d1e45"><section disp-level="1" id="abg16-c130-s1"><div id="MPS_d1e47"><h2 class="topicontainer" id="toc_d1e47">Clinical presentation of cellulitis and erysipelas<span class="pull-right"><i class="fa fa-angle-down banner-head-topic"></i></span></h2></div><div class="colapsecontent" id="ftxttoc_d1e47" style="display:none"><div class="icon-wrapper"><ul class="topic-icons text-right showIcon"><li><a class="feedback" data-contentwrapper=".mycontent" data-placement="bottom" data-tooltip="true" id="sendFeedBack" onclick="sendFeedbackSection('abg16-c130-s1','toc_d1e47','Cellulitis and erysipelas: Clinical presentation of cellulitis and erysipelas')" title="Feedback on section"></a></li><li><a class="favourite" data-contentwrapper=".myfavourite" data-placement="bottom" data-tooltip="true" id="CellulitisanderysipelasClinicalpresentationofcellulitisanderysipelas" onclick="addFavourite('abg16-c130-s1','toc_d1e47','Cellulitis and erysipelas: Clinical presentation of cellulitis and erysipelas')" title="Add section to favourites"></a></li></ul></div><div class="clearfix"></div><div id="abg16-c130-para1"><p class="removeElement">Cellulitis and erysipelas present as diffuse, spreading areas of skin erythema. Lymphangitis, lymphadenopathy, fever or other systemic features may be present.</p></div><div id="abg16-c130-para2"><p class="removeElement">In erysipelas, the affected area is raised, with a clear line of demarcation between infected and noninfected tissue. It classically involves the facial skin in a butterfly pattern, but also commonly affects a lower limb. Erysipelas is most commonly seen in infants, young children and older adults.</p></div><div id="abg16-c130-para3"><p class="removeElement">Cellulitis extends further into the dermis than erysipelas, involving the subcutaneous tissue. Cellulitis in children is often <a href="\tglcontent\Antibiotic\periorbital-orbital-cellulitis.html" id="MPS_02859209600115544" title="Periorbital (preseptal) and orbital (postseptal) cellulitis">periorbital</a>.</p></div><div id="abg16-c130-para01"><fn fn-type="margin-note" id="abg16-c130-mar-fn1"><p> <span>Many conditions present similarly to cellulitis&#x2014;always consider differential diagnoses.</span></p></fn></div><div id="abg16-c130-para5"><p class="removeElement">Cellulitis can complicate wounds (eg cuts, abrasions), insect bites or scabies.</p></div><div id="abg16-c130-para6"><p class="removeElement">Conditions that can be misdiagnosed as cellulitis include: acute <a href="\tglcontent\Dermatology\dermatitis.html?sectionId=dmg-c06-s10#dmg-c06-s10" id="MPS_03331953824237073" title="Contact dermatitis">contact dermatitis</a>; <a href="\tglcontent\Antibiotic\septic-bursitis.html" id="MPS_045472791474019414" title="Septic bursitis">septic bursitis</a>; <a href="\tglcontent\Rheumatology\gout.html" id="MPS_04374797996382551" title="Gout">gout</a>; and acute lipodermatosclerosis, which commonly occurs in obese people with venous insufficiency. Bilateral lower limb cellulitis is rare; always consider differential diagnoses.</p></div></div></section><section disp-level="1" id="abg16-c130-s2"><div id="MPS_d1e64"><h2 class="topicontainer" id="toc_d1e64">Aetiology of cellulitis and erysipelas<span class="pull-right"><i class="fa fa-angle-down banner-head-topic"></i></span></h2></div><div class="colapsecontent" id="ftxttoc_d1e64" style="display:none"><div class="icon-wrapper"><ul class="topic-icons text-right showIcon"><li><a class="feedback" data-contentwrapper=".mycontent" data-placement="bottom" data-tooltip="true" id="sendFeedBack" onclick="sendFeedbackSection('abg16-c130-s2','toc_d1e64','Cellulitis and erysipelas: Aetiology of cellulitis and erysipelas')" title="Feedback on section"></a></li><li><a class="favourite" data-contentwrapper=".myfavourite" data-placement="bottom" data-tooltip="true" id="CellulitisanderysipelasAetiologyofcellulitisanderysipelas" onclick="addFavourite('abg16-c130-s2','toc_d1e64','Cellulitis and erysipelas: Aetiology of cellulitis and erysipelas')" title="Add section to favourites"></a></li></ul></div><div class="clearfix"></div><div id="abg16-c130-para7"><p class="removeElement">Erysipelas is almost always caused by <i>Streptococcus pyogenes</i> (group A streptococcus).</p></div><div id="abg16-c130-para8"><p class="removeElement"><i>S. pyogenes</i>, or another <i>Streptococcus</i> species (eg group B, C or G), is the most common cause of nonpurulent, recurrent cellulitis (eg associated with lymphoedema) or spontaneous, rapidly spreading cellulitis. Cellulitis caused by <i>Staphylococcus aureus</i> (including methicillin-resistant strains [MRSA]) is less frequent and is often associated with penetrating trauma, ulceration or an abscess. Purulent cellulitis is typically caused by <i>S. aureus</i>.</p></div><div id="abg16-c130-para9"><p class="removeElement">In specific circumstances, other organisms can cause cellulitis (eg <a href="\tglcontent\Antibiotic\water-immersed-wound-infections.html?sectionId=abg16-c181-s6#abg16-c181-s6-1" id="MPS_08579726426857162" title="Aeromonas species">Aeromonas species</a>&#x000A0;following fresh water exposure, <a href="\tglcontent\Antibiotic\water-immersed-wound-infections.html?sectionId=abg16-c181-s6#abg16-c181-s6-2" id="MPS_05815190724266139" title="Vibrio species">Vibrio species</a>&#x000A0;following salt water exposure, Gram-negative bacteria in patients with chronic liver disease). In immunocompromised patients, a broad range of organisms can cause infection including Gram-negative bacteria, fungi and mycobacteria.</p></div></div></section><section disp-level="1" id="abg16-c130-s3"><div id="MPS_d1e93"><h2 class="topicontainer" id="toc_d1e93">Principles of managing cellulitis and erysipelas<span class="pull-right"><i class="fa fa-angle-down banner-head-topic"></i></span></h2></div><div class="colapsecontent" id="ftxttoc_d1e93" style="display:none"><div class="icon-wrapper"><ul class="topic-icons text-right showIcon"><li><a class="feedback" data-contentwrapper=".mycontent" data-placement="bottom" data-tooltip="true" id="sendFeedBack" onclick="sendFeedbackSection('abg16-c130-s3','toc_d1e93','Cellulitis and erysipelas: Principles of managing cellulitis and erysipelas')" title="Feedback on section"></a></li><li><a class="favourite" data-contentwrapper=".myfavourite" data-placement="bottom" data-tooltip="true" id="CellulitisanderysipelasPrinciplesofmanagingcellulitisanderysipelas" onclick="addFavourite('abg16-c130-s3','toc_d1e93','Cellulitis and erysipelas: Principles of managing cellulitis and erysipelas')" title="Add section to favourites"></a></li></ul></div><div class="clearfix"></div><section disp-level="2" id="abg16-c130-s4"><div id="MPS_d1e96"><h3 id="toc_d1e96">Nonantibiotic management</h3></div><div id="abg16-c130-para10"><p class="removeElement">Assess patients with cellulitis associated with systemic features for <a href="\tglcontent\Antibiotic\skin-soft-tissue-necrotising-infections.html?sectionId=abg16-c136-s1#abg16-c136-s1" id="MPS_03128377339912469" title="Diagnosing necrotising skin and soft tissue infections">necrotising fasciitis or myonecrosis</a>.</p></div><div id="abg16-c130-para11"><p class="removeElement">Evaluate patients with cellulitis for drainable sources of infection (such as an abscess). If a drainable source is identified, collect a sample for culture and susceptibility testing. It can be difficult to determine if there is an underlying abscess with fluctuation if significant overlying induration is present; soft tissue ultrasonography can aid diagnosis and should be considered if available.</p></div><div id="abg16-c130-para12"><p class="removeElement">Rest and elevation of the affected area improves clinical response. If the skin has eroded, use <a href="\tglcontent\Ulcer and Wound Management\ulcer-and-wound-dressings.html?sectionId=lwg2-c17-s4#tlwg2-c17-tbl3" id="MPS_037014337818156373" title="Low-adherent dressings (Table 15.13)">nonadhesive&#x000A0;dressings</a>. Address contributing factors such as oedema (eg due to lymphoedema or cardiac failure) or venous insufficiency.</p></div></section><section disp-level="2" id="abg16-c130-s5"><div id="MPS_d1e105"><h3 id="toc_d1e105">Antibiotic choice</h3></div><div id="abg16-c130-para13"><p class="removeElement">For management of periorbital and orbital cellulitis, see <a href="\tglcontent\Antibiotic\periorbital-orbital-cellulitis.html" id="MPS_018756742378854296" title="Periorbital (preseptal) and orbital (postseptal) cellulitis">here</a>.</p></div><div id="abg16-c130-para14"><p class="removeElement">Oral therapy is adequate for <a href="\tglcontent\Antibiotic\cellulitis-erysipelas.html?sectionId=abg16-c130-s7#abg16-c130-s7" id="MPS_06536423590431981" title="Empirical therapy for cellulitis and erysipelas without systemic features">cellulitis and erysipelas not associated with systemic features of infection</a>, and is usually suitable for patients with a single systemic feature of infection.</p></div><div id="abg16-c130-para15"><p class="removeElement">Initial intravenous therapy is usually required for adults with two or more of the following systemic features of infection:<list id="abg16-c130-L1" isedited="no" islabel="no" list-type="bullet"/></p><ul><li><list-item id="abg16-c130-list-item1"><div id="abg16-c130-para16">temperature more than 38&#x00B0;C or less than 36&#x00B0;C</div></list-item></li><li><list-item id="abg16-c130-list-item2"><div id="abg16-c130-para17">heart rate more than 90 beats/minute</div></list-item></li><li><list-item id="abg16-c130-list-item3"><div id="abg16-c130-para18">respiratory rate more than 20 breaths/minute</div></list-item></li><li><list-item id="abg16-c130-list-item4"><div id="abg16-c130-para19">white cell count more than 12 &#x00D7; 10<sup id="MPS_d1e126">9</sup>/L or less than 4 &#x00D7; 10<sup id="MPS_d1e129">9</sup>/L, or more than 10% immature (band) forms.</div></list-item></li></ul></div><div id="abg16-c130-para20"><p class="removeElement">Intravenous therapy is also used for patients unable to tolerate oral therapy, and may be required for immunocompromised patients or patients with comorbidities that increase the risk of rapid disease progression (eg diabetes), even if they do not have two or more systemic features of infection.</p></div><div id="abg16-c130-para21"><p class="removeElement">For patients with cellulitis associated with two or more systemic features, antibiotic therapy targeting <i>S. pyogenes</i> and <i>S. aureus</i> is adequate if <a href="\tglcontent\Antibiotic\cellulitis-erysipelas.html?sectionId=abg16-c130-s8#abg16-c130-s8" id="MPS_038401352525897514" title="Empirical therapy for cellulitis and erysipelas with systemic features">cellulitis is not associated with hypotension, septic shock or rapid progression of systemic features</a>. Broader-spectrum therapy is required for <a href="\tglcontent\Antibiotic\cellulitis-erysipelas.html?sectionId=abg16-c130-s9#abg16-c130-s9" id="MPS_06564166218802554" title="Empirical therapy for cellulitis associated with hypotension, septic shock or rapid progression of systemic features">cellulitis associated with hypotension, septic shock or rapid worsening of systemic features</a>.</p></div><div id="abg16-c130-para22"><p class="removeElement">If intravenous therapy is used initially, consider an early switch to oral therapy if the patient is stable; in some cases, one or two doses of intravenous therapy is sufficient.</p></div></section><section disp-level="2" id="abg16-c130-s6"><div id="MPS_d1e145"><h3 id="toc_d1e145">Response to therapy</h3></div><div id="abg16-c130-para23"><p class="removeElement">Local symptoms (eg erythematous rash) can worsen for up to 48 hours after effective therapy is started, but systemic features should improve. Therefore, when assessing response to treatment, consider systemic features as well as the extent of cellulitis. If the patient remains systemically well but local symptoms worsen, it may not be necessary to adjust antibiotic therapy.</p></div><div id="abg16-c130-para24"><p class="removeElement">Local symptoms may not respond to antibiotic therapy for up to 5 days. However, if there is no improvement in local symptoms at 48 hours, reconsider the diagnosis, look for a drainable source of infection, and reconsider antibiotic choice (see <a href="\tglcontent\Antibiotic\cellulitis-erysipelas.html?sectionId=abg16-c130-s2#abg16-c130-s2" id="MPS_032520807991044" title="Aetiology of cellulitis and erysipelas">Aetiology of cellulitis and erysipelas</a>).</p></div><div id="abg16-c130-para25"><p class="removeElement">If reassessment does not change the diagnosis or empirical regimen, or locate a drainable source of infection, and the patient has clearly not improved, consider switching to intravenous therapy. <a href="\tglcontent\Antibiotic\outpatient-parenteral-antimicrobial-therapy.html" id="MPS_07492444410834194" title="Community-based parenteral antimicrobial therapy">Community-based parenteral antimicrobial therapy</a> may be appropriate. Clinical prerequisites for community-based therapy of cellulitis include:<list id="abg16-c130-L2" isedited="no" islabel="no" list-type="bullet"/></p><ul><li><list-item id="abg16-c130-list-item5"><div id="abg16-c130-para26">a collection or abscess requiring surgical drainage is not clinically suspected</div></list-item></li><li><list-item id="abg16-c130-list-item6"><div id="abg16-c130-para27">limb compromise from swelling is not a risk</div></list-item></li><li><list-item id="abg16-c130-list-item7"><div id="abg16-c130-para28">infection of the deeper tissues, such as myositis, fasciitis or osteomyelitis has been excluded</div></list-item></li><li><list-item id="abg16-c130-list-item8"><div id="abg16-c130-para29">the patient does not have risk factors for rapid progression of infection (such as poorly controlled diabetes or significant immune compromise).</div></list-item></li></ul></div><div id="abg16-c130-para30"><p class="removeElement">Because of the strong inflammatory response characteristic of cellulitis, it is common for patients to have residual signs of inflammation at the end of treatment.</p></div></section></div></section><section disp-level="1" id="abg16-c130-s7"><div id="MPS_d1e169"><h2 class="topicontainer" id="toc_d1e169">Empirical therapy for cellulitis and erysipelas without systemic features<span class="pull-right"><i class="fa fa-angle-down banner-head-topic"></i></span></h2></div><div class="colapsecontent" id="ftxttoc_d1e169" style="display:none"><div class="icon-wrapper"><ul class="topic-icons text-right showIcon"><li><a class="feedback" data-contentwrapper=".mycontent" data-placement="bottom" data-tooltip="true" id="sendFeedBack" onclick="sendFeedbackSection('abg16-c130-s7','toc_d1e169','Cellulitis and erysipelas: Empirical therapy for cellulitis and erysipelas without systemic features')" title="Feedback on section"></a></li><li><a class="favourite" data-contentwrapper=".myfavourite" data-placement="bottom" data-tooltip="true" id="CellulitisanderysipelasEmpiricaltherapyforcellulitisanderysipelaswithoutsystemicfeatures" onclick="addFavourite('abg16-c130-s7','toc_d1e169','Cellulitis and erysipelas: Empirical therapy for cellulitis and erysipelas without systemic features')" title="Add section to favourites"></a></li></ul></div><div class="clearfix"></div><div id="abg16-c130-para31"><p class="removeElement">For management of periorbital and orbital cellulitis, see <a href="\tglcontent\Antibiotic\periorbital-orbital-cellulitis.html" id="MPS_05018682613469794" title="Periorbital (preseptal) and orbital (postseptal) cellulitis">here</a>.</p></div><div id="abg16-c130-para32"><p class="removeElement">For cellulitis and erysipelas without systemic features, antibiotic choice depends on whether the infection is likely to be caused by <i>Streptococcus pyogenes</i> or <i>Staphylococcus aureus</i> (including community-associated methicillin-resistant <i>S. aureus</i> [CA-MRSA]) (see <a href="\tglcontent\Antibiotic\cellulitis-erysipelas.html?sectionId=abg16-c130-s2#abg16-c130-s2" id="MPS_04576858414382965" title="Aetiology of cellulitis and erysipelas">Aetiology of cellulitis and erysipelas</a>). It is usually appropriate to stop antibiotic therapy after 5 days, even if mild signs of inflammation remain; extend therapy if the infection has not clinically improved by the end of the treatment course.</p></div><div id="abg16-c130-para33"><p class="removeElement">For <b>erysipelas</b>, or if <b><i>S</i>. <i>pyogenes</i></b> is suspected based on clinical presentation (eg nonpurulent, recurrent or spontaneous, rapidly spreading cellulitis), use:</p></div><div class="disp-quote blueBox"  content-type="drugcode" id="MPS_d1e196"><div id="abg16-c130-para34"><table><tr><td class="drugRanking"><span class="rankingBullet">1</span></td><td class="drugTextTD"><p class="drugText"><ext-link bfeed="true" drugcode="phenoxymethylpenicillin" ext-link-type="drugcode" pbs="true" preg="true"><span>phenoxymethylpenicillin</span></ext-link> 500 mg (child: 12.5 mg/kg up to 500 mg) orally, 6-hourly for 5 days <indication class="hidden"><i>cellulitis and erysipelas, empirical therapy</i></indication><div id="PBSphenoxymethylpenicillin0" style="display:none"> </div></p></td><td class="drugIcons"><a class="drugcodes" data-placement="bottom" data-tooltip="true" href="javascript:void(0);" id="apbs0" onClick="getDosageInfo('PBS','phenoxymethylpenicillin','PBSphenoxymethylpenicillin0',event);" title="Check PBS"><img alt="" src="../Images/tg_dosage_pbs.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_p.htm#MPS_d1e352" id="MPS_07211338126807791" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_p.htm#MPS_d1e352" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_p.htm#MPS_d1e352"><img alt="" src="../Images/tg_dosage_pregnancy.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_p.htm#MPS_d1e352" id="MPS_022527230556182776" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_p.htm#MPS_d1e352" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_p.htm#MPS_d1e352"><img alt="" src="../Images/tg_dosage_breastfeeding.png" style="width: 25px;height: 25px;"/></a></td></tr></table></div><div id="abg16-c130-para35"><p class="drugJoiningWord">OR</p></div><div id="abg16-c130-para36"><table><tr><td class="drugRanking"><span class="rankingBullet">1</span></td><td class="drugTextTD"><p class="drugText"><ext-link bfeed="true" drugcode="procaine_benzylpenicillin" ext-link-type="drugcode" pbs="true" preg="true"><span>procaine benzylpenicillin</span></ext-link> 1.5 g (child: 50 mg/kg up to 1.5 g) intramuscularly, daily for at least 3 days. <indication class="hidden"><i>cellulitis and erysipelas</i></indication><div id="PBSprocaine_benzylpenicillin3" style="display:none"> </div></p></td><td class="drugIcons"><a class="drugcodes" data-placement="bottom" data-tooltip="true" href="javascript:void(0);" id="apbs3" onClick="getDosageInfo('PBS','procaine_benzylpenicillin','PBSprocaine_benzylpenicillin3',event);" title="Check PBS"><img alt="" src="../Images/tg_dosage_pbs.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_p.htm#MPS_d1e743" id="MPS_06221703036259616" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_p.htm#MPS_d1e743" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_p.htm#MPS_d1e743"><img alt="" src="../Images/tg_dosage_pregnancy.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_p.htm#MPS_d1e743" id="MPS_023449385586926663" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_p.htm#MPS_d1e743" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_p.htm#MPS_d1e743"><img alt="" src="../Images/tg_dosage_breastfeeding.png" style="width: 25px;height: 25px;"/></a></td></tr></table></div></div><div id="abg16-c130-para37"><p class="removeElement">For patients with <b>delayed nonsevere</b> <a href="\tglcontent\Antibiotic\antimicrobial-hypersensitivity.html?sectionId=abg16-c166-s13#abg16-c166-s13" id="MPS_07770149747780817" title="Management of patients reporting hypersensitivity to penicillins">hypersensitivity to penicillins</a>, cefalexin can be used in most cases [<a href="javascript:void(0);" id="MPS_d2e3784" onclick="navigateRef('n_abg16-c130-fn2','toc_d1e169')" title="Note 1">Note 1</a>]. Use:</p></div><div class="disp-quote blueBox"  content-type="drugcode" id="MPS_d1e217"><div id="abg16-c130-para38"><table><tr><td class="drugWORanking"/><td class="drugTextTD"><p class="drugText"><ext-link bfeed="true" drugcode="cefalexin" ext-link-type="drugcode" pbs="true" preg="true"><span>cefalexin</span></ext-link> 500 mg (child: 12.5 mg/kg up to 500 mg) orally, 6-hourly for 5 days. <indication class="hidden"><i>cellulitis and erysipelas</i></indication><div id="PBScefalexin6" style="display:none"> </div></p></td><td class="drugIcons"><a class="drugcodes" data-placement="bottom" data-tooltip="true" href="javascript:void(0);" id="apbs6" onClick="getDosageInfo('PBS','cefalexin','PBScefalexin6',event);" title="Check PBS"><img alt="" src="../Images/tg_dosage_pbs.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e296001" id="MPS_04122133887663224" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_c.htm#MPS_d1e296001" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e296001"><img alt="" src="../Images/tg_dosage_pregnancy.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e296001" id="MPS_03370991825801519" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_c.htm#MPS_d1e296001" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e296001"><img alt="" src="../Images/tg_dosage_breastfeeding.png" style="width: 25px;height: 25px;"/></a></td></tr></table></div></div><div id="abg16-c130-para39"><p class="removeElement">For patients with <b>immediate (nonsevere or severe)</b> or <b>delayed severe</b> <a href="\tglcontent\Antibiotic\antimicrobial-hypersensitivity.html?sectionId=abg16-c166-s13#abg16-c166-s13" id="MPS_06031020688667663" title="Management of patients reporting hypersensitivity to penicillins">hypersensitivity to penicillins</a>, use:</p></div><div class="disp-quote blueBox"  content-type="drugcode" id="MPS_d1e230"><div id="abg16-c130-para40"><table><tr><td class="drugWORanking"/><td class="drugTextTD"><p class="drugText"><ext-link bfeed="true" drugcode="clindamycin" ext-link-type="drugcode" pbs="true" preg="true"><span>clindamycin</span></ext-link> 450 mg (child: 10 mg/kg up to 450 mg) orally, 8-hourly for 5 days [<a href="javascript:void(0);" id="MPS_d2e4300" onclick="navigateRef('n_abg16-c130-fn3','toc_d1e169')" title="Note 2">Note 2</a>]. <indication class="hidden"><i>cellulitis and erysipelas, without systemic features</i></indication><div id="PBSclindamycin9" style="display:none"> </div></p></td><td class="drugIcons"><a class="drugcodes" data-placement="bottom" data-tooltip="true" href="javascript:void(0);" id="apbs9" onClick="getDosageInfo('PBS','clindamycin','PBSclindamycin9',event);" title="Check PBS"><img alt="" src="../Images/tg_dosage_pbs.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e643" id="MPS_0030583616598411467" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_c.htm#MPS_d1e643" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e643"><img alt="" src="../Images/tg_dosage_pregnancy.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e643" id="MPS_039421839042451867" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_c.htm#MPS_d1e643" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e643"><img alt="" src="../Images/tg_dosage_breastfeeding.png" style="width: 25px;height: 25px;"/></a></td></tr></table></div></div><div id="abg16-c130-para41"><p class="removeElement">For <b>purulent</b> cellulitis (eg associated abscess), or if <b><i>S. aureus</i></b> is suspected based on clinical presentation (eg penetrating trauma, associated ulcer), use:</p></div><div class="disp-quote blueBox"  content-type="drugcode" id="MPS_d1e247"><div id="abg16-c130-para42"><table><tr><td class="drugRanking"><span class="rankingBullet">1</span></td><td class="drugTextTD"><p class="drugText"><ext-link bfeed="true" drugcode="dicloxacillin" ext-link-type="drugcode" pbs="true" preg="true"><span>dicloxacillin</span></ext-link> 500 mg (child: 12.5 mg/kg up to 500 mg) orally, 6-hourly for 5 days <indication class="hidden"><i>cellulitis and erysipelas</i></indication><div id="PBSdicloxacillin12" style="display:none"> </div></p></td><td class="drugIcons"><a class="drugcodes" data-placement="bottom" data-tooltip="true" href="javascript:void(0);" id="apbs12" onClick="getDosageInfo('PBS','dicloxacillin','PBSdicloxacillin12',event);" title="Check PBS"><img alt="" src="../Images/tg_dosage_pbs.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_d.htm#MPS_d1e324" id="MPS_07724813993555033" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_d.htm#MPS_d1e324" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_d.htm#MPS_d1e324"><img alt="" src="../Images/tg_dosage_pregnancy.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_d.htm#MPS_d1e324" id="MPS_04982784509006566" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_d.htm#MPS_d1e324" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_d.htm#MPS_d1e324"><img alt="" src="../Images/tg_dosage_breastfeeding.png" style="width: 25px;height: 25px;"/></a></td></tr></table></div><div id="abg16-c130-para43"><p class="drugJoiningWord">OR</p></div><div id="abg16-c130-para44"><table><tr><td class="drugRanking"><span class="rankingBullet">1</span></td><td class="drugTextTD"><p class="drugText"><ext-link bfeed="true" drugcode="flucloxacillin" ext-link-type="drugcode" pbs="true" preg="true"><span>flucloxacillin</span></ext-link> 500 mg (child: 12.5 mg/kg up to 500 mg) orally, 6-hourly for 5 days. <indication class="hidden"><i>cellulitis and erysipelas, without systemic features</i></indication><div id="PBSflucloxacillin15" style="display:none"> </div></p></td><td class="drugIcons"><a class="drugcodes" data-placement="bottom" data-tooltip="true" href="javascript:void(0);" id="apbs15" onClick="getDosageInfo('PBS','flucloxacillin','PBSflucloxacillin15',event);" title="Check PBS"><img alt="" src="../Images/tg_dosage_pbs.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_f.htm#MPS_d1e216" id="MPS_003444328297831345" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_f.htm#MPS_d1e216" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_f.htm#MPS_d1e216"><img alt="" src="../Images/tg_dosage_pregnancy.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_f.htm#MPS_d1e216" id="MPS_07884438908701885" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_f.htm#MPS_d1e216" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_f.htm#MPS_d1e216"><img alt="" src="../Images/tg_dosage_breastfeeding.png" style="width: 25px;height: 25px;"/></a></td></tr></table></div></div><div id="abg16-c130-para45"><p class="removeElement">Cefalexin is often preferred to dicloxacillin or flucloxacillin in children, because the liquid formulation is better tolerated. In most cases, it can also be used for patients with <b>delayed nonsevere</b> <a href="\tglcontent\Antibiotic\antimicrobial-hypersensitivity.html?sectionId=abg16-c166-s13#abg16-c166-s13" id="MPS_07222943502980497" title="Management of patients reporting hypersensitivity to penicillins">hypersensitivity to penicillins</a> [<a href="javascript:void(0);" id="MPS_d2e7255" onclick="navigateRef('n_abg16-c130-fn2','toc_d1e169')" title="Note 1">Note 1</a>]. Use:</p></div><div class="disp-quote blueBox"  content-type="drugcode" id="MPS_d1e269"><div id="abg16-c130-para46"><table><tr><td class="drugWORanking"/><td class="drugTextTD"><p class="drugText"><ext-link bfeed="true" drugcode="cefalexin" ext-link-type="drugcode" pbs="true" preg="true"><span>cefalexin</span></ext-link> 500 mg (child: 12.5 mg/kg up to 500 mg) orally, 6-hourly for 5 days.<div id="PBScefalexin18" style="display:none"> </div></p></td><td class="drugIcons"><a class="drugcodes" data-placement="bottom" data-tooltip="true" href="javascript:void(0);" id="apbs18" onClick="getDosageInfo('PBS','cefalexin','PBScefalexin18',event);" title="Check PBS"><img alt="" src="../Images/tg_dosage_pbs.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e296001" id="MPS_0708337124363351" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_c.htm#MPS_d1e296001" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e296001"><img alt="" src="../Images/tg_dosage_pregnancy.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e296001" id="MPS_08197600488723658" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_c.htm#MPS_d1e296001" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e296001"><img alt="" src="../Images/tg_dosage_breastfeeding.png" style="width: 25px;height: 25px;"/></a></td></tr></table></div></div><div id="abg16-c130-para47"><p class="removeElement">For patients at increased risk of <b>MRSA</b> infection (see <a href="\tglcontent\Antibiotic\sepsis-empirical-regimens.html?sectionId=abg16-c127-s1#abg16-c127-box2" id="MPS_02032640539337618" title="Risk factors for infection with methicillin-resistant Staphylococcus aureus (Box 2.31)">Box 2.31</a>), or who have <b>immediate (nonsevere or severe)</b> or <b>delayed severe</b> <a href="\tglcontent\Antibiotic\antimicrobial-hypersensitivity.html?sectionId=abg16-c166-s13#abg16-c166-s13" id="MPS_02890995487024708" title="Management of patients reporting hypersensitivity to penicillins">hypersensitivity to penicillins</a>, use:</p></div><div class="disp-quote blueBox"  content-type="drugcode" id="MPS_d1e285"><div id="abg16-c130-para48"><table><tr><td class="drugRanking"><span class="rankingBullet">1</span></td><td class="drugTextTD"><p class="drugText"><ext-link bfeed="true" drugcode="trimethoprim_plus_sulfamethoxazole" ext-link-type="drugcode" pbs="true" preg="true"><span>trimethoprim+sulfamethoxazole</span></ext-link> 160+800 mg (child 1 month or older: 4+20 mg/kg up to 160+800 mg) orally, 12-hourly for 5 days <indication class="hidden"><i>cellulitis and erysipelas</i></indication><div id="PBStrimethoprim_plus_sulfamethoxazole21" style="display:none"> </div></p></td><td class="drugIcons"><a class="drugcodes" data-placement="bottom" data-tooltip="true" href="javascript:void(0);" id="apbs21" onClick="getDosageInfo('PBS','trimethoprim_plus_sulfamethoxazole','PBStrimethoprim_plus_sulfamethoxazole21',event);" title="Check PBS"><img alt="" src="../Images/tg_dosage_pbs.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_t.htm#MPS_d1e669" id="MPS_038441544247692994" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_t.htm#MPS_d1e669" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_t.htm#MPS_d1e669"><img alt="" src="../Images/tg_dosage_pregnancy.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_t.htm#MPS_d1e669" id="MPS_07748160573359391" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_t.htm#MPS_d1e669" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_t.htm#MPS_d1e669"><img alt="" src="../Images/tg_dosage_breastfeeding.png" style="width: 25px;height: 25px;"/></a></td></tr></table></div><div id="abg16-c130-para49"><p class="drugJoiningWord">OR</p></div><div id="abg16-c130-para50"><table><tr><td class="drugRanking"><span class="rankingBullet">2</span></td><td class="drugTextTD"><p class="drugText"><ext-link bfeed="true" drugcode="clindamycin" ext-link-type="drugcode" id="MPS_d1e295" pbs="true" preg="true"><span>clindamycin</span></ext-link> 450 mg (child: 10 mg/kg up to 450 mg) orally, 8-hourly for 5 days [<a href="javascript:void(0);" id="MPS_d2e1913" onclick="navigateRef('n_abg16-c130-fn3','toc_d1e169')" title="Note 2">Note 2</a>].<div id="PBSclindamycin24" style="display:none"> </div></p></td><td class="drugIcons"><a class="drugcodes" data-placement="bottom" data-tooltip="true" href="javascript:void(0);" id="apbs24" onClick="getDosageInfo('PBS','clindamycin','PBSclindamycin24',event);" title="Check PBS"><img alt="" src="../Images/tg_dosage_pbs.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e643" id="MPS_004773289952790161" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_c.htm#MPS_d1e643" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e643"><img alt="" src="../Images/tg_dosage_pregnancy.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e643" id="MPS_07637177912087978" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_c.htm#MPS_d1e643" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e643"><img alt="" src="../Images/tg_dosage_breastfeeding.png" style="width: 25px;height: 25px;"/></a></td></tr></table></div></div><fn fn-type="footnote" id="n_abg16-c130-fn2"><p> <span>Note 1: &#x000A0;It is safe to use cefalexin in patients who had a delayed nonsevere reaction to a penicillin in the distant past. It is also safe to use cefalexin in patients who have had a delayed nonsevere reaction recently, unless the reaction involved amoxicillin or ampicillin, because cross-reactivity between these drugs is possible. For patients who have had a recent delayed nonsevere reaction to amoxicillin or ampicillin, use the drug recommended for patients with immediate (nonsevere or severe) or delayed severe hypersensitivity. </span></p></fn><fn fn-type="footnote" id="n_abg16-c130-fn3"><p> <span>Note 2: &#x000A0;An oral liquid formulation of clindamycin is not commercially available; for formulation options for children or people with swallowing difficulties, see the <i>Don&#x2019;t Rush to Crush Handbook</i>, published by the Society of Hospital Pharmacists of Australia [<a href="http://www.shpa.org.au/drtc3" id="url-ref_55" target="_blank">URL</a>]. </span></p></fn></div></section><section disp-level="1" id="abg16-c130-s8"><div id="MPS_d1e339"><h2 class="topicontainer" id="toc_d1e339">Empirical therapy for cellulitis and erysipelas with systemic features<span class="pull-right"><i class="fa fa-angle-down banner-head-topic"></i></span></h2></div><div class="colapsecontent" id="ftxttoc_d1e339" style="display:none"><div class="icon-wrapper"><ul class="topic-icons text-right showIcon"><li><a class="feedback" data-contentwrapper=".mycontent" data-placement="bottom" data-tooltip="true" id="sendFeedBack" onclick="sendFeedbackSection('abg16-c130-s8','toc_d1e339','Cellulitis and erysipelas: Empirical therapy for cellulitis and erysipelas with systemic features')" title="Feedback on section"></a></li><li><a class="favourite" data-contentwrapper=".myfavourite" data-placement="bottom" data-tooltip="true" id="CellulitisanderysipelasEmpiricaltherapyforcellulitisanderysipelaswithsystemicfeatures" onclick="addFavourite('abg16-c130-s8','toc_d1e339','Cellulitis and erysipelas: Empirical therapy for cellulitis and erysipelas with systemic features')" title="Add section to favourites"></a></li></ul></div><div class="clearfix"></div><div id="abg16-c130-para51"><p class="removeElement">For management of periorbital and orbital cellulitis, see <a href="\tglcontent\Antibiotic\periorbital-orbital-cellulitis.html" id="MPS_0541331570192569" title="Periorbital (preseptal) and orbital (postseptal) cellulitis">here</a>.</p></div><div id="abg16-c130-para52"><p class="removeElement">The following advice applies to patients with cellulitis or erysipelas associated with two or more systemic symptoms but not associated with hypotension, septic shock or rapid progression of systemic features. Assess patients for <a href="\tglcontent\Antibiotic\skin-soft-tissue-necrotising-infections.html?sectionId=abg16-c136-s1#abg16-c136-s1" id="MPS_012923129773719855" title="Diagnosing necrotising skin and soft tissue infections">necrotising fasciitis or myonecrosis</a>.</p></div><div id="abg16-c130-para53"><p class="removeElement">Ceftriaxone and cefotaxime have a broad spectrum of activity that is not required for cellulitis that is likely to be caused by streptococci or staphylococci.</p></div><div id="abg16-c130-para54"><p class="removeElement">For <b>erysipelas</b>, or if <b><i>Streptococcus pyogenes</i></b> is suspected based on clinical presentation (eg nonpurulent, recurrent or spontaneous, rapidly spreading cellulitis), use:</p></div><div class="disp-quote blueBox"  content-type="drugcode" id="MPS_d1e356"><div id="abg16-c130-para55"><table><tr><td class="drugWORanking"/><td class="drugTextTD"><p class="drugText"><ext-link bfeed="true" drugcode="benzylpenicillin" ext-link-type="drugcode" pbs="true" preg="true"><span>benzylpenicillin</span></ext-link> 1.2 g (child: 50 mg/kg up to 1.2 g) intravenously, 6-hourly. <indication class="hidden"><i>cellulitis and erysipelas</i></indication><div id="PBSbenzylpenicillin27" style="display:none"> </div></p></td><td class="drugIcons"><a class="drugcodes" data-placement="bottom" data-tooltip="true" href="javascript:void(0);" id="apbs27" onClick="getDosageInfo('PBS','benzylpenicillin','PBSbenzylpenicillin27',event);" title="Check PBS"><img alt="" src="../Images/tg_dosage_pbs.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_b.htm#MPS_d1e216" id="MPS_09201527412081749" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_b.htm#MPS_d1e216" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_b.htm#MPS_d1e216"><img alt="" src="../Images/tg_dosage_pregnancy.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_b.htm#MPS_d1e216" id="MPS_02222388899010601" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_b.htm#MPS_d1e216" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_b.htm#MPS_d1e216"><img alt="" src="../Images/tg_dosage_breastfeeding.png" style="width: 25px;height: 25px;"/></a></td></tr></table></div></div><div id="abg16-c130-para56"><p class="removeElement">For <b>purulent</b> cellulitis (eg associated abscess), or if <b><i>Staphylococcus aureus</i></b> is suspected based on clinical presentation (eg penetrating trauma, associated ulcer), use:</p></div><div class="disp-quote blueBox"  content-type="drugcode" id="MPS_d1e370"><div id="abg16-c130-para57"><table><tr><td class="drugWORanking"/><td class="drugTextTD"><p class="drugText"><ext-link bfeed="true" drugcode="flucloxacillin" ext-link-type="drugcode" pbs="true" preg="true"><span>flucloxacillin</span></ext-link> 2 g (child: 50 mg/kg up to 2 g) intravenously, 6-hourly. <indication class="hidden"><i>cellulitis and erysipelas, with systemic features</i></indication><div id="PBSflucloxacillin30" style="display:none"> </div></p></td><td class="drugIcons"><a class="drugcodes" data-placement="bottom" data-tooltip="true" href="javascript:void(0);" id="apbs30" onClick="getDosageInfo('PBS','flucloxacillin','PBSflucloxacillin30',event);" title="Check PBS"><img alt="" src="../Images/tg_dosage_pbs.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_f.htm#MPS_d1e216" id="MPS_007999160694107244" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_f.htm#MPS_d1e216" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_f.htm#MPS_d1e216"><img alt="" src="../Images/tg_dosage_pregnancy.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_f.htm#MPS_d1e216" id="MPS_06190195776978973" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_f.htm#MPS_d1e216" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_f.htm#MPS_d1e216"><img alt="" src="../Images/tg_dosage_breastfeeding.png" style="width: 25px;height: 25px;"/></a></td></tr></table></div></div><div id="abg16-c130-para58"><p class="removeElement">For patients with purulent cellulitis or in whom <i>S. aureus</i> is suspected based on clinical presentation, who are at increased risk of methicillin-resistant <i>S. aureus</i> (<b>MRSA</b>) infection (see <a href="\tglcontent\Antibiotic\sepsis-empirical-regimens.html?sectionId=abg16-c127-s1#abg16-c127-box2" id="MPS_05233605289270546" title="Risk factors for infection with methicillin-resistant Staphylococcus aureus (Box 2.31)">Box 2.31</a>), use:</p></div><div class="disp-quote blueBox"  content-type="drugcode" id="MPS_d1e386"><div id="abg16-c130-para59"><table><tr><td class="drugWORanking"/><td class="drugTextTD"><p class="drugText"><ext-link bfeed="true" drugcode="vancomycin" ext-link-type="drugcode" pbs="true" preg="true"><span>vancomycin</span></ext-link> intravenously; see <a href="\tglcontent\Antibiotic\vancomycin-use-principles.html" id="MPS_013228406606766474" title="Principles of vancomycin use">Principles of vancomycin use</a> for dosage and principles of use. <indication class="hidden"><i>cellulitis and erysipelas</i></indication><div id="PBSvancomycin33" style="display:none"> </div></p></td><td class="drugIcons"><a class="drugcodes" data-placement="bottom" data-tooltip="true" href="javascript:void(0);" id="apbs33" onClick="getDosageInfo('PBS','vancomycin','PBSvancomycin33',event);" title="Check PBS"><img alt="" src="../Images/tg_dosage_pbs.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_v.htm#MPS_d1e111" id="MPS_037447732716314386" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_v.htm#MPS_d1e111" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_v.htm#MPS_d1e111"><img alt="" src="../Images/tg_dosage_pregnancy.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_v.htm#MPS_d1e111" id="MPS_03702465668252368" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_v.htm#MPS_d1e111" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_v.htm#MPS_d1e111"><img alt="" src="../Images/tg_dosage_breastfeeding.png" style="width: 25px;height: 25px;"/></a></td></tr></table></div></div><div id="abg16-c130-para60"><p class="removeElement">In some regions, based on local community-associated MRSA (CA-MRSA) susceptibility patterns, clindamycin or lincomycin is a suitable alternative to vancomycin:</p></div><div class="disp-quote blueBox"  content-type="drugcode" id="MPS_d1e394"><div id="abg16-c130-para61"><table><tr><td class="drugRanking"><span class="rankingBullet">1</span></td><td class="drugTextTD"><p class="drugText"><ext-link bfeed="true" drugcode="clindamycin" ext-link-type="drugcode" pbs="true" preg="true"><span>clindamycin</span></ext-link> 600 mg (child: 15 mg/kg up to 600 mg) intravenously, 8-hourly <indication class="hidden"><i>cellulitis and erysipelas, with systemic features</i></indication><div id="PBSclindamycin36" style="display:none"> </div></p></td><td class="drugIcons"><a class="drugcodes" data-placement="bottom" data-tooltip="true" href="javascript:void(0);" id="apbs36" onClick="getDosageInfo('PBS','clindamycin','PBSclindamycin36',event);" title="Check PBS"><img alt="" src="../Images/tg_dosage_pbs.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e643" id="MPS_064213196754595" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_c.htm#MPS_d1e643" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e643"><img alt="" src="../Images/tg_dosage_pregnancy.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e643" id="MPS_08191782144704716" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_c.htm#MPS_d1e643" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e643"><img alt="" src="../Images/tg_dosage_breastfeeding.png" style="width: 25px;height: 25px;"/></a></td></tr></table></div><div id="abg16-c130-para62"><p class="drugJoiningWord">OR</p></div><div id="abg16-c130-para63"><table><tr><td class="drugRanking"><span class="rankingBullet">2</span></td><td class="drugTextTD"><p class="drugText"><ext-link bfeed="true" drugcode="lincomycin" ext-link-type="drugcode" pbs="true" preg="true"><span>lincomycin</span></ext-link> 600 mg (child: 15 mg/kg up to 600 mg) intravenously, 8-hourly. <indication class="hidden"><i>cellulitis and erysipelas</i></indication><div id="PBSlincomycin39" style="display:none"> </div></p></td><td class="drugIcons"><a class="drugcodes" data-placement="bottom" data-tooltip="true" href="javascript:void(0);" id="apbs39" onClick="getDosageInfo('PBS','lincomycin','PBSlincomycin39',event);" title="Check PBS"><img alt="" src="../Images/tg_dosage_pbs.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_l.htm#MPS_d1e310" id="MPS_04345550934018969" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_l.htm#MPS_d1e310" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_l.htm#MPS_d1e310"><img alt="" src="../Images/tg_dosage_pregnancy.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_l.htm#MPS_d1e310" id="MPS_08283703510142189" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_l.htm#MPS_d1e310" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_l.htm#MPS_d1e310"><img alt="" src="../Images/tg_dosage_breastfeeding.png" style="width: 25px;height: 25px;"/></a></td></tr></table></div></div><div id="abg16-c130-para64"><p class="removeElement">For patients with <b>immediate nonsevere</b> or <b>delayed nonsevere</b> <a href="\tglcontent\Antibiotic\antimicrobial-hypersensitivity.html?sectionId=abg16-c166-s13#abg16-c166-s13" id="MPS_06942972354078214" title="Management of patients reporting hypersensitivity to penicillins">hypersensitivity to penicillins</a>, replace benzylpenicillin or flucloxacillin with cefazolin. use:</p></div><div class="disp-quote blueBox"  content-type="drugcode" id="MPS_d1e415"><div id="abg16-c130-para65"><table><tr><td class="drugWORanking"/><td class="drugTextTD"><p class="drugText"><ext-link bfeed="true" drugcode="cefazolin" ext-link-type="drugcode" pbs="true" preg="true"><span>cefazolin</span></ext-link> 2 g (child: 50 mg/kg up to 2 g) intravenously, 8-hourly. <indication class="hidden"><i>cellulitis and erysipelas</i></indication><div id="PBScefazolin42" style="display:none"> </div></p></td><td class="drugIcons"><a class="drugcodes" data-placement="bottom" data-tooltip="true" href="javascript:void(0);" id="apbs42" onClick="getDosageInfo('PBS','cefazolin','PBScefazolin42',event);" title="Check PBS"><img alt="" src="../Images/tg_dosage_pbs.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e306" id="MPS_026212622133815655" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_c.htm#MPS_d1e306" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e306"><img alt="" src="../Images/tg_dosage_pregnancy.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e306" id="MPS_0931191954534442" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_c.htm#MPS_d1e306" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e306"><img alt="" src="../Images/tg_dosage_breastfeeding.png" style="width: 25px;height: 25px;"/></a></td></tr></table></div></div><div id="abg16-c130-para66"><p class="removeElement">For patients with <b>immediate severe</b> or <b>delayed severe</b> <a href="\tglcontent\Antibiotic\antimicrobial-hypersensitivity.html?sectionId=abg16-c166-s13#abg16-c166-s13" id="MPS_06176971313762776" title="Management of patients reporting hypersensitivity to penicillins">hypersensitivity to penicillins</a>, replace benzylpenicillin or flucloxacillin with vancomycin (see dosage above).</p></div><div id="abg16-c130-para67"><p class="removeElement">If <a href="\tglcontent\Antibiotic\outpatient-parenteral-antimicrobial-therapy.html" id="MPS_021433264109384798" title="Community-based parenteral antimicrobial therapy">community-based parenteral antimicrobial therapy</a>&#x000A0;is appropriate for adult patients, use:</p></div><div class="disp-quote blueBox"  content-type="drugcode" id="MPS_d1e430"><div id="abg16-c130-para68"><table><tr><td class="drugRanking"><span class="rankingBullet">1</span></td><td class="drugTextTD"><p class="drugText"><ext-link bfeed="true" drugcode="cefazolin" ext-link-type="drugcode" pbs="true" preg="true"><span>cefazolin</span></ext-link> 2 g intravenously, daily<list id="abg16-c130-L7" isedited="no" islabel="no" list-type="none"/><div id="PBScefazolin45" style="display:none"> </div></p></td><td class="drugIcons"><a class="drugcodes" data-placement="bottom" data-tooltip="true" href="javascript:void(0);" id="apbs45" onClick="getDosageInfo('PBS','cefazolin','PBScefazolin45',event);" title="Check PBS"><img alt="" src="../Images/tg_dosage_pbs.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e306" id="MPS_06682217601440605" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_c.htm#MPS_d1e306" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e306"><img alt="" src="../Images/tg_dosage_pregnancy.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e306" id="MPS_09641587435640966" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_c.htm#MPS_d1e306" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e306"><img alt="" src="../Images/tg_dosage_breastfeeding.png" style="width: 25px;height: 25px;"/></a></td></tr></table><ul style="list-style:none"><li><list-item id="abg16-c130-list-item51"><div class="drugJoiningWord" id="abg16-c130-para69">PLUS</div></list-item></li><li><list-item id="abg16-c130-list-item52"><table><tr><td class="drugWORanking"/><td class="drugTextTD"><p class="drugText"><ext-link bfeed="true" drugcode="probenecid" ext-link-type="drugcode" pbs="true" preg="true">probenecid</ext-link> 1 g orally, daily <indication class="hidden"><i>cellulitis and erysipelas</i></indication><div id="PBSprobenecid48" style="display:none"> </div></p></td><td class="drugIcons"><a class="drugcodes" data-placement="bottom" data-tooltip="true" href="javascript:void(0);" id="apbs48" onClick="getDosageInfo('PBS','probenecid','PBSprobenecid48',event);" title="Check PBS"><img alt="" src="../Images/tg_dosage_pbs.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_p.htm#MPS_d1e723" id="MPS_07838858666990312" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_p.htm#MPS_d1e723" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_p.htm#MPS_d1e723"><img alt="" src="../Images/tg_dosage_pregnancy.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_p.htm#MPS_d1e723" id="MPS_07832445858266235" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_p.htm#MPS_d1e723" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_p.htm#MPS_d1e723"><img alt="" src="../Images/tg_dosage_breastfeeding.png" style="width: 25px;height: 25px;"/></a></td></tr></table></list-item></li></ul></div><div id="abg16-c130-para71"><p class="drugJoiningWord">OR</p></div><div id="abg16-c130-para72"><table><tr><td class="drugRanking"><span class="rankingBullet">1</span></td><td class="drugTextTD"><p class="drugText"><ext-link bfeed="true" drugcode="cefazolin" ext-link-type="drugcode" pbs="true" preg="true"><span>cefazolin</span></ext-link> 2 g intravenously, 12-hourly.<div id="PBScefazolin51" style="display:none"> </div></p></td><td class="drugIcons"><a class="drugcodes" data-placement="bottom" data-tooltip="true" href="javascript:void(0);" id="apbs51" onClick="getDosageInfo('PBS','cefazolin','PBScefazolin51',event);" title="Check PBS"><img alt="" src="../Images/tg_dosage_pbs.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e306" id="MPS_07676680579787369" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_c.htm#MPS_d1e306" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e306"><img alt="" src="../Images/tg_dosage_pregnancy.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e306" id="MPS_021250621467346953" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_c.htm#MPS_d1e306" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_c.htm#MPS_d1e306"><img alt="" src="../Images/tg_dosage_breastfeeding.png" style="width: 25px;height: 25px;"/></a></td></tr></table></div></div><div id="abg16-c130-para73"><p class="removeElement">Community-based parenteral antimicrobial therapy is rarely used for children with cellulitis; if community-based intravenous therapy is necessary, consult a service experienced in providing care for children for advice on choice of therapy.</p></div><div id="abg16-c130-para74"><p class="removeElement">When systemic features have improved, switch to oral therapy (see <a href="\tglcontent\Antibiotic\cellulitis-erysipelas.html?sectionId=abg16-c130-s7#abg16-c130-s7" id="MPS_08508532600778524" title="Empirical therapy for cellulitis and erysipelas without systemic features">Cellulitis and erysipelas without systemic features</a>); if systemic symptoms rapidly resolve, one or two doses of intravenous therapy may be sufficient. A total <b>duration of therapy</b> of 5 to 10 days (intravenous + oral) is recommended.</p></div></div></section><section disp-level="1" id="abg16-c130-s9"><div id="MPS_d1e460"><h2 class="topicontainer" id="toc_d1e460">Empirical therapy for cellulitis associated with hypotension, septic shock or rapid progression of systemic features<span class="pull-right"><i class="fa fa-angle-down banner-head-topic"></i></span></h2></div><div class="colapsecontent" id="ftxttoc_d1e460" style="display:none"><div class="icon-wrapper"><ul class="topic-icons text-right showIcon"><li><a class="feedback" data-contentwrapper=".mycontent" data-placement="bottom" data-tooltip="true" id="sendFeedBack" onclick="sendFeedbackSection('abg16-c130-s9','toc_d1e460','Cellulitis and erysipelas: Empirical therapy for cellulitis associated with hypotension, septic shock or rapid progression of systemic features')" title="Feedback on section"></a></li><li><a class="favourite" data-contentwrapper=".myfavourite" data-placement="bottom" data-tooltip="true" id="CellulitisanderysipelasEmpiricaltherapyforcellulitisassociatedwithhypotensionsepticshockorrapidprogressionofsystemicfeatures" onclick="addFavourite('abg16-c130-s9','toc_d1e460','Cellulitis and erysipelas: Empirical therapy for cellulitis associated with hypotension, septic shock or rapid progression of systemic features')" title="Add section to favourites"></a></li></ul></div><div class="clearfix"></div><div id="abg16-c130-para75"><p class="removeElement">Broad-spectrum therapy is required initially for patients with cellulitis associated with hypotension, septic shock or rapid progression of systemic features. For initial empirical therapy, use the regimens in <a href="\tglcontent\Antibiotic\skin-soft-tissue-necrotising-infections.html?sectionId=abg16-c136-s3#abg16-c136-s3" id="MPS_014343723890441318" title="Empirical therapy for necrotising skin and soft tissue infection">necrotising skin and soft tissue infections</a>. Seek expert advice for ongoing therapy.</p></div><div id="abg16-c130-para76"><p class="removeElement">Start antibiotic therapy <b>within 1 hour</b> of the patient presenting to medical care or, for a ward-based patient, developing sepsis or septic shock; antibiotics should be given immediately after appropriate samples are taken for culture. For nonantibiotic management of sepsis or septic shock, see <a href="\tglcontent\Antibiotic\sepsis-principles-managing.html?sectionId=abg16-c126-s3#abg16-c126-s3" id="MPS_03353996250273108" title="Early intervention for sepsis or septic shock">Early intervention for sepsis or septic shock</a>.</p></div><div id="abg16-c130-para77"><p class="removeElement">A total <b>duration of therapy</b> of up to 2 weeks (intravenous + oral) is recommended.</p></div></div></section><section disp-level="1" id="abg16-c130-s10"><div id="MPS_d1e475"><h2 class="topicontainer" id="toc_d1e475">Preventing recurrent cellulitis<span class="pull-right"><i class="fa fa-angle-down banner-head-topic"></i></span></h2></div><div class="colapsecontent" id="ftxttoc_d1e475" style="display:none"><div class="icon-wrapper"><ul class="topic-icons text-right showIcon"><li><a class="feedback" data-contentwrapper=".mycontent" data-placement="bottom" data-tooltip="true" id="sendFeedBack" onclick="sendFeedbackSection('abg16-c130-s10','toc_d1e475','Cellulitis and erysipelas: Preventing recurrent cellulitis')" title="Feedback on section"></a></li><li><a class="favourite" data-contentwrapper=".myfavourite" data-placement="bottom" data-tooltip="true" id="CellulitisanderysipelasPreventingrecurrentcellulitis" onclick="addFavourite('abg16-c130-s10','toc_d1e475','Cellulitis and erysipelas: Preventing recurrent cellulitis')" title="Add section to favourites"></a></li></ul></div><div class="clearfix"></div><div id="abg16-c130-para78"><p class="removeElement">Factors that predispose patients to recurrent cellulitis include tinea infection of the feet, fissured dermatitis, lymphoedema and lymphatic malformation.</p></div><div id="abg16-c130-para79"><p class="removeElement">Examine patients&#x2019; feet for <a href="\tglcontent\Dermatology\tinea.html" id="MPS_06295508348281005" title="Tinea">tinea infection</a>.</p></div><div id="abg16-c130-para80"><p class="removeElement">For patients with leg oedema, venous insufficiency or a leg ulcer, see <a href="\tglcontent\Ulcer and Wound Management\assessing-patients-with-an-ulcer-or-wound.html" id="MPS_019737154578958327" title="Assessing patients with an ulcer or wound">Assessing patients with an ulcer or wound</a>.</p></div><div id="abg16-c130-para81"><p class="removeElement">Patients with persistent risk factors for recurrent cellulitis can be provided with a prescription for phenoxymethylpenicillin (see <a href="\tglcontent\Antibiotic\cellulitis-erysipelas.html?sectionId=abg16-c130-s7#abg16-c130-s7" id="MPS_04063217535341761" title="Empirical therapy for cellulitis and erysipelas without systemic features">Cellulitis and erysipelas without systemic features</a>) so they can start treatment as soon as they develop symptoms. Alternatively, for patients with frequent recurrences, prophylaxis can be considered:</p></div><div class="disp-quote blueBox"  content-type="drugcode" id="MPS_d1e485"><div id="abg16-c130-para82"><table><tr><td class="drugWORanking"/><td class="drugTextTD"><p class="drugText"><ext-link bfeed="true" drugcode="phenoxymethylpenicillin" ext-link-type="drugcode" pbs="true" preg="true"><span>phenoxymethylpenicillin</span></ext-link> 250 mg orally, twice daily for up to 6 months initially, then reviewed regularly. <indication class="hidden"><i>cellulitis and erysipelas, prevention</i></indication><div id="PBSphenoxymethylpenicillin54" style="display:none"> </div></p></td><td class="drugIcons"><a class="drugcodes" data-placement="bottom" data-tooltip="true" href="javascript:void(0);" id="apbs54" onClick="getDosageInfo('PBS','phenoxymethylpenicillin','PBSphenoxymethylpenicillin54',event);" title="Check PBS"><img alt="" src="../Images/tg_dosage_pbs.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_p.htm#MPS_d1e352" id="MPS_05921632101354957" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_p.htm#MPS_d1e352" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_p.htm#MPS_d1e352"><img alt="" src="../Images/tg_dosage_pregnancy.png" style="width: 25px;height: 25px;"/></a><a class="drugcodes" data-placement="bottom" data-tooltip="true" druglink="true" href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_p.htm#MPS_d1e352" id="MPS_08832618960596783" title="quicklinks/type=Pregnancy%20and%20breastfeeding?bf=breastfeeding_p.htm#MPS_d1e352" xlink_href="/tglcontent/quicklinks/pregnancybreastfeeding.htm?bf=breastfeeding_p.htm#MPS_d1e352"><img alt="" src="../Images/tg_dosage_breastfeeding.png" style="width: 25px;height: 25px;"/></a></td></tr></table></div></div></div></section></span><back id="MPS_d1e490"><div><h2 class="topicontainer" id="MPS_d1e491">Key references<span class="pull-right"><i class="fa fa-angle-down banner-head-topic"></i></span></h2></div><div class="colapsecontent" id="ftxtMPS_d1e491" style="display:none"><div class="icon-wrapper"><ul class="topic-icons text-right showIcon"><li><a class="feedback" data-contentwrapper=".mycontent" data-placement="bottom" data-tooltip="true" id="sendFeedBack" onclick="sendFeedbackSection('MPS_d1e490','MPS_d1e491','Cellulitis and erysipelas: Key references')" title="Feedback on section"></a></li><li><a class="favourite" data-contentwrapper=".myfavourite" data-placement="bottom" data-tooltip="true" id="CellulitisanderysipelasKeyreferences" onclick="addFavourite('MPS_d1e490','MPS_d1e491','Cellulitis and erysipelas: Key references')" title="Add section to favourites"></a></li></ul></div><div class="clearfix"></div><ref-list content-type="references" id="abg16-c130-ref1"><ref-title id="MPS_d1e494"> </ref-title><ref><p>Bowen AC, Carapetis JR, Currie BJ, Fowler V Jr, Chambers HF, Tong SYC. Sulfamethoxazole-trimethoprim (cotrimoxazole) for skin and soft tissue infections including impetigo, cellulitis, and abscess.&#x000A0; Open Forum Infect Dis 2017;4(4):ofx232. <a href="http://www.ncbi.nlm.nih.gov/pubmed/29255730" id="MPS_d1e63623" target="_blank" xlink_href="http://www.ncbi.nlm.nih.gov/pubmed/29255730" xmlns_xlink="http://www.w3.org/1999/xlink"><img alt="" class="figure" id="yr7cel1EaO" mime-subtype="gif" src="Images/pubmed.gif" style="display:inline;" xlink_href="pubmed.gif"/></a>.</p></ref><ref><p>Bruun T, Oppegaard O, Kittang BR, Mylvaganam H, Langeland N, Skrede S. Etiology of cellulitis and clinical prediction of streptococcal disease: A prospective study.&#x000A0; Open Forum Infect Dis 2016;3(1):ofv181. <a href="http://www.ncbi.nlm.nih.gov/pubmed/26734653" id="MPS_d1e15711" target="_blank" xlink_href="http://www.ncbi.nlm.nih.gov/pubmed/26734653" xmlns_xlink="http://www.w3.org/1999/xlink"><img alt="" class="figure" id="XPfLYRrqZ5" mime-subtype="gif" src="Images/pubmed.gif" style="display:inline;" xlink_href="pubmed.gif"/></a>.</p></ref><ref id="abg16-c130-bib1"><p>&#x000A0;Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004;164(15):1669&#x2013;74. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15302637" id="MPS_d1e563" target="_blank" xlink_href="http://www.ncbi.nlm.nih.gov/pubmed/15302637" xmlns_xlink="http://www.w3.org/1999/xlink"><img alt="" class="figure" id="TJoVxDwsfZ" mime-subtype="gif" src="Images/pubmed.gif" style="display:inline;" xlink_href="pubmed.gif"/></a></p></ref><ref id="abg16-c130-bib5"><p>&#x000A0;McMullan BJ, Andresen D, Blyth CC, Avent ML, Bowen AC, Britton PN, et al. Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines. Lancet Infect Dis 2016;16(8):e139&#x2013;52. <a href="http://www.ncbi.nlm.nih.gov/pubmed/27321363" id="MPS_d1e810" target="_blank" xlink_href="http://www.ncbi.nlm.nih.gov/pubmed/27321363" xmlns_xlink="http://www.w3.org/1999/xlink"><img alt="" class="figure" id="gGdZo12jM5" mime-subtype="gif" src="Images/pubmed.gif" style="display:inline;" xlink_href="pubmed.gif"/></a></p></ref><ref><p>Moran GJ, Krishnadasan A, Mower WR, Abrahamian FM, LoVecchio F, Steele MT, et al. Effect of cephalexin plus trimethoprim-sulfamethoxazole vs cephalexin alone on clinical cure of uncomplicated cellulitis: A randomized clinical trial.&#x000A0; JAMA 2017;317(20):2088&#x2013;2096&#x000A0;<a href="http://www.ncbi.nlm.nih.gov/pubmed/28535235" id="MPS_d1e75156" target="_blank" xlink_href="http://www.ncbi.nlm.nih.gov/pubmed/28535235" xmlns_xlink="http://www.w3.org/1999/xlink"><img alt="" class="figure" id="bWtHMZfkTp" mime-subtype="gif" src="Images/pubmed.gif" style="display:inline;" xlink_href="pubmed.gif"/></a>.</p></ref><ref><p>Pallin DJ, Binder WD, Allen MB, Lederman M, Parmar S, Filbin MR, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial.&#x000A0; Clin Infect Dis 2013;56(12):1754&#x2013;1762&#x000A0;<a href="http://www.ncbi.nlm.nih.gov/pubmed/23457080" id="MPS_d1e39241" target="_blank" xlink_href="http://www.ncbi.nlm.nih.gov/pubmed/23457080" xmlns_xlink="http://www.w3.org/1999/xlink"><img alt="" class="figure" id="clpFdIfZDd" mime-subtype="gif" src="Images/pubmed.gif" style="display:inline;" xlink_href="pubmed.gif"/></a>.</p></ref><ref id="abg16-c130-bib6"><p>&#x000A0;Raff AB, Kroshinsky D. Cellulitis: A review. JAMA 2016;316(3):325&#x2013;37<a href="http://www.ncbi.nlm.nih.gov/pubmed/27434444" id="MPS_d1e850" target="_blank" xlink_href="http://www.ncbi.nlm.nih.gov/pubmed/27434444" xmlns_xlink="http://www.w3.org/1999/xlink"><img alt="" class="figure" id="uszkr1I6FG" mime-subtype="gif" src="Images/pubmed.gif" style="display:inline;" xlink_href="pubmed.gif"/></a>.</p></ref><ref id="abg16-c130-bib7"><p>&#x000A0;Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014;59(2):e10&#x2013;52. <a href="http://www.ncbi.nlm.nih.gov/pubmed/24973422" id="MPS_d1e919" target="_blank" xlink_href="http://www.ncbi.nlm.nih.gov/pubmed/24973422" xmlns_xlink="http://www.w3.org/1999/xlink"><img alt="" class="figure" id="EH9if5KbYA" mime-subtype="gif" src="Images/pubmed.gif" style="display:inline;" xlink_href="pubmed.gif"/></a></p></ref></ref-list></div></back><div class="reviseddate"><p>Published April 2019. Amended December 2019. © Therapeutic Guidelines Ltd (eTG March 2021 edition)</p></div></div></body></html>